New drug combo shows promise in shrinking tough breast cancer before surgery
NCT ID NCT07016399
First seen Nov 01, 2025 · Last updated Jun 14, 2026 · Updated 27 times
Summary
This study tests whether adding the drug darolutamide to standard chemotherapy and immunotherapy before surgery can shrink tumors more effectively in people with early-stage androgen receptor positive triple-negative breast cancer. About 51 participants will receive either standard therapy alone or standard therapy plus darolutamide. The goal is to see if the combination reduces tumor activity and improves surgical outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vanderbilt University/Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.